APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nocturia

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nocturia Market Outlook and Growth Opportunities 2026

29 December 2025216 pages

Choose your research edition.

Industry ResearchNocturia Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Nocturia Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Nocturia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nocturia Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Nocturia Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Nocturia market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nocturia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nocturia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nocturia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nocturia market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nocturia market include Abbott, Allergan, APOTEX INC, Astellas Pharma, Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Ferring Pharmaceuticals and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nocturia market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nocturia and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nocturia revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nocturia market.

Nocturia Segment by Company

Abbott

Allergan

APOTEX INC

Astellas Pharma

Astra Zeneca

Bristol-Myers Squibb

Eli Lilly

Ferring Pharmaceuticals

GlaxoSmithKline

Johnson & Johnson

Merck

Mylan

Novartis

Pfizer

Rechon Life Science AB

Sagent Pharmaceuticals

Sanofi

Sun Pharmaceutical Industries Ltd.

Teva

Chengdu Leer Pharmaceutical

Fosun Pharma

Hainan Zhonghe Pharmaceutical

Nanjing Xingyin Pharmaceutical Group

Hybio Pharmaceutical

Zhejiang Conba Pharmaceutical

Nocturia Segment by Type

Desmopressin

Diuretics

Anticholinergic Drugs

Alpha Blockers

Others

Nocturia Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Nocturia Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nocturia status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nocturia key companies, revenue, market share, and recent developments.

3. To split the Nocturia breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nocturia market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nocturia significant trends, drivers, influence factors in global and regions.

6. To analyze Nocturia competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nocturia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nocturia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nocturia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nocturia industry.

Chapter 3: Detailed analysis of Nocturia company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nocturia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nocturia in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nocturia Industry Trends Table 2. Nocturia Industry Drivers Table 3. Nocturia Industry Opportunities and Challenges Table 4. Nocturia Industry Restraints Table 5. Global Nocturia Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nocturia Revenue Share by Company (2021-2026) Table 7. Global Nocturia Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nocturia Key Company Manufacturing Base & Headquarters Table 9. Global Nocturia Company, Product Type & Application Table 10. Global Nocturia Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nocturia by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Desmopressin Table 15. Significant Companies of Diuretics Table 16. Significant Companies of Anticholinergic Drugs Table 17. Significant Companies of Alpha Blockers Table 18. Significant Companies of Others Table 19. Global Nocturia Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Nocturia Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Nocturia Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Nocturia Sales Value Share by Type (2021-2026) Table 23. Global Nocturia Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Retail Pharmacies Table 25. Significant Companies of Online Pharmacies Table 26. Significant Companies of Hospital Pharmacies Table 27. Global Nocturia Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Nocturia Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Nocturia Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Nocturia Sales Value Share by Application (2021-2026) Table 31. Global Nocturia Sales Value Share by Application (2027-2032) Table 32. Global Nocturia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Nocturia Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Nocturia Sales Value Share by Region (2021-2026) Table 35. Global Nocturia Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Nocturia Sales Value Share by Region (2027-2032) Table 37. Global Nocturia Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Nocturia Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Nocturia Sales Value Market Share by Country (2021-2026) Table 40. Global Nocturia Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Nocturia Sales Value Market Share by Country (2027-2032) Table 42. Abbott Company Information Table 43. Abbott Business Overview Table 44. Abbott Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Abbott Nocturia Product Portfolio Table 46. Abbott Recent Development Table 47. Allergan Company Information Table 48. Allergan Business Overview Table 49. Allergan Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Allergan Nocturia Product Portfolio Table 51. Allergan Recent Development Table 52. APOTEX INC Company Information Table 53. APOTEX INC Business Overview Table 54. APOTEX INC Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. APOTEX INC Nocturia Product Portfolio Table 56. APOTEX INC Recent Development Table 57. Astellas Pharma Company Information Table 58. Astellas Pharma Business Overview Table 59. Astellas Pharma Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Astellas Pharma Nocturia Product Portfolio Table 61. Astellas Pharma Recent Development Table 62. Astra Zeneca Company Information Table 63. Astra Zeneca Business Overview Table 64. Astra Zeneca Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Astra Zeneca Nocturia Product Portfolio Table 66. Astra Zeneca Recent Development Table 67. Bristol-Myers Squibb Company Information Table 68. Bristol-Myers Squibb Business Overview Table 69. Bristol-Myers Squibb Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Bristol-Myers Squibb Nocturia Product Portfolio Table 71. Bristol-Myers Squibb Recent Development Table 72. Eli Lilly Company Information Table 73. Eli Lilly Business Overview Table 74. Eli Lilly Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Eli Lilly Nocturia Product Portfolio Table 76. Eli Lilly Recent Development Table 77. Ferring Pharmaceuticals Company Information Table 78. Ferring Pharmaceuticals Business Overview Table 79. Ferring Pharmaceuticals Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Ferring Pharmaceuticals Nocturia Product Portfolio Table 81. Ferring Pharmaceuticals Recent Development Table 82. GlaxoSmithKline Company Information Table 83. GlaxoSmithKline Business Overview Table 84. GlaxoSmithKline Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. GlaxoSmithKline Nocturia Product Portfolio Table 86. GlaxoSmithKline Recent Development Table 87. Johnson & Johnson Company Information Table 88. Johnson & Johnson Business Overview Table 89. Johnson & Johnson Nocturia Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Johnson & Johnson Nocturia Product Portfolio Table 91. Johnson & Johnson Recent Development Table 92. Merck Company Information Table 93. Merck Business Overview Table 94. Merck Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Merck Nocturia Product Portfolio Table 96. Merck Recent Development Table 97. Mylan Company Information Table 98. Mylan Business Overview Table 99. Mylan Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Mylan Nocturia Product Portfolio Table 101. Mylan Recent Development Table 102. Novartis Company Information Table 103. Novartis Business Overview Table 104. Novartis Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Novartis Nocturia Product Portfolio Table 106. Novartis Recent Development Table 107. Pfizer Company Information Table 108. Pfizer Business Overview Table 109. Pfizer Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Pfizer Nocturia Product Portfolio Table 111. Pfizer Recent Development Table 112. Rechon Life Science AB Company Information Table 113. Rechon Life Science AB Business Overview Table 114. Rechon Life Science AB Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Rechon Life Science AB Nocturia Product Portfolio Table 116. Rechon Life Science AB Recent Development Table 117. Sagent Pharmaceuticals Company Information Table 118. Sagent Pharmaceuticals Business Overview Table 119. Sagent Pharmaceuticals Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Sagent Pharmaceuticals Nocturia Product Portfolio Table 121. Sagent Pharmaceuticals Recent Development Table 122. Sanofi Company Information Table 123. Sanofi Business Overview Table 124. Sanofi Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Sanofi Nocturia Product Portfolio Table 126. Sanofi Recent Development Table 127. Sun Pharmaceutical Industries Ltd. Company Information Table 128. Sun Pharmaceutical Industries Ltd. Business Overview Table 129. Sun Pharmaceutical Industries Ltd. Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Sun Pharmaceutical Industries Ltd. Nocturia Product Portfolio Table 131. Sun Pharmaceutical Industries Ltd. Recent Development Table 132. Teva Company Information Table 133. Teva Business Overview Table 134. Teva Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Teva Nocturia Product Portfolio Table 136. Teva Recent Development Table 137. Chengdu Leer Pharmaceutical Company Information Table 138. Chengdu Leer Pharmaceutical Business Overview Table 139. Chengdu Leer Pharmaceutical Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Chengdu Leer Pharmaceutical Nocturia Product Portfolio Table 141. Chengdu Leer Pharmaceutical Recent Development Table 142. Fosun Pharma Company Information Table 143. Fosun Pharma Business Overview Table 144. Fosun Pharma Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Fosun Pharma Nocturia Product Portfolio Table 146. Fosun Pharma Recent Development Table 147. Hainan Zhonghe Pharmaceutical Company Information Table 148. Hainan Zhonghe Pharmaceutical Business Overview Table 149. Hainan Zhonghe Pharmaceutical Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Hainan Zhonghe Pharmaceutical Nocturia Product Portfolio Table 151. Hainan Zhonghe Pharmaceutical Recent Development Table 152. Nanjing Xingyin Pharmaceutical Group Company Information Table 153. Nanjing Xingyin Pharmaceutical Group Business Overview Table 154. Nanjing Xingyin Pharmaceutical Group Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Nanjing Xingyin Pharmaceutical Group Nocturia Product Portfolio Table 156. Nanjing Xingyin Pharmaceutical Group Recent Development Table 157. Hybio Pharmaceutical Company Information Table 158. Hybio Pharmaceutical Business Overview Table 159. Hybio Pharmaceutical Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Hybio Pharmaceutical Nocturia Product Portfolio Table 161. Hybio Pharmaceutical Recent Development Table 162. Zhejiang Conba Pharmaceutical Company Information Table 163. Zhejiang Conba Pharmaceutical Business Overview Table 164. Zhejiang Conba Pharmaceutical Nocturia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Zhejiang Conba Pharmaceutical Nocturia Product Portfolio Table 166. Zhejiang Conba Pharmaceutical Recent Development Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Nocturia Product Image Figure 2. Global Nocturia Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nocturia Market Size (2021-2032) & (US$ Million) Figure 4. Global Nocturia Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Desmopressin Image Figure 8. Diuretics Image Figure 9. Anticholinergic Drugs Image Figure 10. Alpha Blockers Image Figure 11. Others Image Figure 12. Global Nocturia Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Nocturia Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Nocturia Sales Value Share by Type (2021-2032) Figure 15. Retail Pharmacies Image Figure 16. Online Pharmacies Image Figure 17. Hospital Pharmacies Image Figure 18. Global Nocturia Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nocturia Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Nocturia Sales Value Share by Application (2021-2032) Figure 21. Global Nocturia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Nocturia Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Nocturia Sales Value (2021-2032) & (US$ Million) Figure 24. North America Nocturia Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Nocturia Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Nocturia Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Nocturia Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Nocturia Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Nocturia Sales Value (2021-2032) & (US$ Million) Figure 30. South America Nocturia Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Nocturia Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Nocturia Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Nocturia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Nocturia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Nocturia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Desmopressin
  • Diuretics
  • Anticholinergic Drugs
  • Alpha Blockers
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Abbott
  • Allergan
  • APOTEX INC
  • Astellas Pharma
  • Astra Zeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Ferring Pharmaceuticals
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Mylan
  • Novartis
  • Pfizer
  • Rechon Life Science AB
  • Sagent Pharmaceuticals
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva
  • Chengdu Leer Pharmaceutical
  • Fosun Pharma
  • Hainan Zhonghe Pharmaceutical
  • Nanjing Xingyin Pharmaceutical Group
  • Hybio Pharmaceutical
  • Zhejiang Conba Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nocturia Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nocturia Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nocturia Market Dynamics
  1. 2.1 Nocturia Industry Trends
  2. 2.2 Nocturia Industry Drivers
  3. 2.3 Nocturia Industry Opportunities and Challenges
  4. 2.4 Nocturia Industry Restraints
3 Nocturia Market by Company
  1. 3.1 Global Nocturia Company Revenue Ranking in 2025
  2. 3.2 Global Nocturia Revenue by Company (2021-2026)
  3. 3.3 Global Nocturia Company Ranking (2024-2026)
  4. 3.4 Global Nocturia Company Manufacturing Base and Headquarters
  5. 3.5 Global Nocturia Company Product Type and Application
  6. 3.6 Global Nocturia Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nocturia Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nocturia Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nocturia Market by Type
  1. 4.1 Nocturia Type Introduction
  2. 4.1.1 Desmopressin
  3. 4.1.2 Diuretics
  4. 4.1.3 Anticholinergic Drugs
  5. 4.1.4 Alpha Blockers
  6. 4.1.5 Others
  7. 4.2 Global Nocturia Sales Value by Type
  8. 4.2.1 Global Nocturia Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Nocturia Sales Value by Type (2021-2032)
  10. 4.2.3 Global Nocturia Sales Value Share by Type (2021-2032)
5 Nocturia Market by Application
  1. 5.1 Nocturia Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Nocturia Sales Value by Application
  6. 5.2.1 Global Nocturia Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nocturia Sales Value by Application (2021-2032)
  8. 5.2.3 Global Nocturia Sales Value Share by Application (2021-2032)
6 Nocturia Regional Value Analysis
  1. 6.1 Global Nocturia Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nocturia Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nocturia Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nocturia Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nocturia Sales Value (2021-2032)
  7. 6.3.2 North America Nocturia Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nocturia Sales Value (2021-2032)
  10. 6.4.2 Europe Nocturia Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nocturia Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nocturia Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nocturia Sales Value (2021-2032)
  16. 6.6.2 South America Nocturia Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nocturia Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nocturia Sales Value Share by Country, 2025 VS 2032
7 Nocturia Country-level Value Analysis
  1. 7.1 Global Nocturia Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nocturia Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nocturia Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nocturia Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nocturia Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nocturia Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nocturia Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nocturia Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nocturia Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nocturia Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nocturia Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nocturia Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nocturia Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nocturia Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nocturia Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nocturia Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nocturia Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nocturia Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nocturia Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nocturia Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nocturia Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nocturia Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nocturia Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nocturia Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nocturia Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nocturia Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nocturia Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nocturia Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nocturia Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nocturia Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nocturia Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nocturia Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nocturia Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nocturia Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nocturia Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nocturia Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nocturia Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nocturia Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nocturia Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nocturia Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nocturia Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nocturia Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nocturia Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nocturia Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nocturia Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nocturia Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nocturia Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nocturia Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nocturia Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nocturia Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nocturia Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nocturia Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nocturia Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nocturia Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nocturia Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nocturia Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nocturia Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nocturia Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nocturia Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nocturia Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nocturia Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nocturia Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nocturia Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nocturia Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nocturia Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nocturia Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nocturia Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nocturia Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nocturia Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nocturia Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nocturia Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nocturia Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nocturia Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nocturia Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nocturia Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nocturia Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nocturia Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nocturia Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nocturia Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nocturia Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nocturia Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nocturia Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nocturia Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nocturia Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nocturia Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nocturia Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nocturia Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nocturia Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Nocturia Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Nocturia Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Allergan
  8. 8.2.1 Allergan Company Information
  9. 8.2.2 Allergan Business Overview
  10. 8.2.3 Allergan Nocturia Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Allergan Nocturia Product Portfolio
  12. 8.2.5 Allergan Recent Developments
  13. 8.3 APOTEX INC
  14. 8.3.1 APOTEX INC Company Information
  15. 8.3.2 APOTEX INC Business Overview
  16. 8.3.3 APOTEX INC Nocturia Revenue and Gross Margin (2021-2026)
  17. 8.3.4 APOTEX INC Nocturia Product Portfolio
  18. 8.3.5 APOTEX INC Recent Developments
  19. 8.4 Astellas Pharma
  20. 8.4.1 Astellas Pharma Company Information
  21. 8.4.2 Astellas Pharma Business Overview
  22. 8.4.3 Astellas Pharma Nocturia Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Astellas Pharma Nocturia Product Portfolio
  24. 8.4.5 Astellas Pharma Recent Developments
  25. 8.5 Astra Zeneca
  26. 8.5.1 Astra Zeneca Company Information
  27. 8.5.2 Astra Zeneca Business Overview
  28. 8.5.3 Astra Zeneca Nocturia Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Astra Zeneca Nocturia Product Portfolio
  30. 8.5.5 Astra Zeneca Recent Developments
  31. 8.6 Bristol-Myers Squibb
  32. 8.6.1 Bristol-Myers Squibb Company Information
  33. 8.6.2 Bristol-Myers Squibb Business Overview
  34. 8.6.3 Bristol-Myers Squibb Nocturia Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Nocturia Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Nocturia Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Nocturia Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Ferring Pharmaceuticals
  44. 8.8.1 Ferring Pharmaceuticals Company Information
  45. 8.8.2 Ferring Pharmaceuticals Business Overview
  46. 8.8.3 Ferring Pharmaceuticals Nocturia Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ferring Pharmaceuticals Nocturia Product Portfolio
  48. 8.8.5 Ferring Pharmaceuticals Recent Developments
  49. 8.9 GlaxoSmithKline
  50. 8.9.1 GlaxoSmithKline Company Information
  51. 8.9.2 GlaxoSmithKline Business Overview
  52. 8.9.3 GlaxoSmithKline Nocturia Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Nocturia Product Portfolio
  54. 8.9.5 GlaxoSmithKline Recent Developments
  55. 8.10 Johnson & Johnson
  56. 8.10.1 Johnson & Johnson Company Information
  57. 8.10.2 Johnson & Johnson Business Overview
  58. 8.10.3 Johnson & Johnson Nocturia Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Johnson & Johnson Nocturia Product Portfolio
  60. 8.10.5 Johnson & Johnson Recent Developments
  61. 8.11 Merck
  62. 8.11.1 Merck Company Information
  63. 8.11.2 Merck Business Overview
  64. 8.11.3 Merck Nocturia Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Merck Nocturia Product Portfolio
  66. 8.11.5 Merck Recent Developments
  67. 8.12 Mylan
  68. 8.12.1 Mylan Company Information
  69. 8.12.2 Mylan Business Overview
  70. 8.12.3 Mylan Nocturia Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Mylan Nocturia Product Portfolio
  72. 8.12.5 Mylan Recent Developments
  73. 8.13 Novartis
  74. 8.13.1 Novartis Company Information
  75. 8.13.2 Novartis Business Overview
  76. 8.13.3 Novartis Nocturia Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Novartis Nocturia Product Portfolio
  78. 8.13.5 Novartis Recent Developments
  79. 8.14 Pfizer
  80. 8.14.1 Pfizer Company Information
  81. 8.14.2 Pfizer Business Overview
  82. 8.14.3 Pfizer Nocturia Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Pfizer Nocturia Product Portfolio
  84. 8.14.5 Pfizer Recent Developments
  85. 8.15 Rechon Life Science AB
  86. 8.15.1 Rechon Life Science AB Company Information
  87. 8.15.2 Rechon Life Science AB Business Overview
  88. 8.15.3 Rechon Life Science AB Nocturia Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Rechon Life Science AB Nocturia Product Portfolio
  90. 8.15.5 Rechon Life Science AB Recent Developments
  91. 8.16 Sagent Pharmaceuticals
  92. 8.16.1 Sagent Pharmaceuticals Company Information
  93. 8.16.2 Sagent Pharmaceuticals Business Overview
  94. 8.16.3 Sagent Pharmaceuticals Nocturia Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Sagent Pharmaceuticals Nocturia Product Portfolio
  96. 8.16.5 Sagent Pharmaceuticals Recent Developments
  97. 8.17 Sanofi
  98. 8.17.1 Sanofi Company Information
  99. 8.17.2 Sanofi Business Overview
  100. 8.17.3 Sanofi Nocturia Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sanofi Nocturia Product Portfolio
  102. 8.17.5 Sanofi Recent Developments
  103. 8.18 Sun Pharmaceutical Industries Ltd.
  104. 8.18.1 Sun Pharmaceutical Industries Ltd. Company Information
  105. 8.18.2 Sun Pharmaceutical Industries Ltd. Business Overview
  106. 8.18.3 Sun Pharmaceutical Industries Ltd. Nocturia Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Sun Pharmaceutical Industries Ltd. Nocturia Product Portfolio
  108. 8.18.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  109. 8.19 Teva
  110. 8.19.1 Teva Company Information
  111. 8.19.2 Teva Business Overview
  112. 8.19.3 Teva Nocturia Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Teva Nocturia Product Portfolio
  114. 8.19.5 Teva Recent Developments
  115. 8.20 Chengdu Leer Pharmaceutical
  116. 8.20.1 Chengdu Leer Pharmaceutical Company Information
  117. 8.20.2 Chengdu Leer Pharmaceutical Business Overview
  118. 8.20.3 Chengdu Leer Pharmaceutical Nocturia Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Chengdu Leer Pharmaceutical Nocturia Product Portfolio
  120. 8.20.5 Chengdu Leer Pharmaceutical Recent Developments
  121. 8.21 Fosun Pharma
  122. 8.21.1 Fosun Pharma Company Information
  123. 8.21.2 Fosun Pharma Business Overview
  124. 8.21.3 Fosun Pharma Nocturia Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Fosun Pharma Nocturia Product Portfolio
  126. 8.21.5 Fosun Pharma Recent Developments
  127. 8.22 Hainan Zhonghe Pharmaceutical
  128. 8.22.1 Hainan Zhonghe Pharmaceutical Company Information
  129. 8.22.2 Hainan Zhonghe Pharmaceutical Business Overview
  130. 8.22.3 Hainan Zhonghe Pharmaceutical Nocturia Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Hainan Zhonghe Pharmaceutical Nocturia Product Portfolio
  132. 8.22.5 Hainan Zhonghe Pharmaceutical Recent Developments
  133. 8.23 Nanjing Xingyin Pharmaceutical Group
  134. 8.23.1 Nanjing Xingyin Pharmaceutical Group Company Information
  135. 8.23.2 Nanjing Xingyin Pharmaceutical Group Business Overview
  136. 8.23.3 Nanjing Xingyin Pharmaceutical Group Nocturia Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Nanjing Xingyin Pharmaceutical Group Nocturia Product Portfolio
  138. 8.23.5 Nanjing Xingyin Pharmaceutical Group Recent Developments
  139. 8.24 Hybio Pharmaceutical
  140. 8.24.1 Hybio Pharmaceutical Company Information
  141. 8.24.2 Hybio Pharmaceutical Business Overview
  142. 8.24.3 Hybio Pharmaceutical Nocturia Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Hybio Pharmaceutical Nocturia Product Portfolio
  144. 8.24.5 Hybio Pharmaceutical Recent Developments
  145. 8.25 Zhejiang Conba Pharmaceutical
  146. 8.25.1 Zhejiang Conba Pharmaceutical Company Information
  147. 8.25.2 Zhejiang Conba Pharmaceutical Business Overview
  148. 8.25.3 Zhejiang Conba Pharmaceutical Nocturia Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Zhejiang Conba Pharmaceutical Nocturia Product Portfolio
  150. 8.25.5 Zhejiang Conba Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst